PharmaMar announces US partner Janssen files NDA for YONDELIS for soft-tissue sarcoma

(Pharmamar) Based on a phase 3 trial in which dacarbazine was used in the comparator arm, Janssen has submitted a NDA for YONDELIS (trabectedin) to the FDA for the treatment of patients with advanced soft tissue sarcoma, including liposarcoma and leiomyosarcoma, who have received prior chemotherapy including an anthracycline.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news